Journal Basic Info
- Impact Factor: 1.995**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
Major Scope
- Transplant Surgery
- General Surgery
- Robotic Surgery
- Bariatric Surgery
- Surgical Oncology
- Pediatric Surgery
- Gastroenterological Surgery
- Orthopaedic Surgery
Abstract
Citation: Clin Surg. 2019;4(1):2639.Case Report | Open Access
Hybrid Combined Flaps and Biomaterials for Preservation of Ischemic Limb Following Massive Ablation of Recurrent Sarcoma
Isao Koshima, Shuhei Yoshida, Shogo Nagamatsu, Kazunori Yokota, Shuji Yamashita, Haruki Mizuta and Dalia Tobbia
International Center for Lymphedema, Hiroshima University, Japan Department of Plastic and Reconstructive Surgery, Hiroshima University, Japan Department of Plastic and Reconstructive Surgery, The University of Tokyo, Japan Department of Plastic and Reconstructive Surgery, National Cancer Center (former Okayama University Medical School, Okayama), Japan Department of Plastic and Reconstructive surgery, Plastische Chirurgie am Klosterstern, Germany
*Correspondance to: Isao Koshima
PDF Full Text DOI: 10.25107/2474-1647.2639
Abstract
A case with recurrent liposarcoma is described in where combined VRAMC flap and emergency free latissimus dorsi musculocutaneous flap as well as artificial hip joint-femur, and femoral vessels were successfully transferred for repair of massive anterior thigh defect. The concept of a hybrid combination with tissue transfers including biomaterials (bone and vessels) can preserve a limb with widely invasive recurrent sarcoma. Emergency free LDMC flap transfer with flow-through pedicle anastomosis is also important to prevent exposure of artificial vessels and bone. In addition, prophylactic LVA is also very important approach for the prevention of postoperative lymphedema as a serious complication after massive resection in the proximal thigh.
Keywords
Cite the article
Koshima I, Yoshida S, Nagamatsu S, Yokota K, Yamashita S, Mizuta H, et al. Hybrid Combined Flaps and Biomaterials for Preservation of Ischemic Limb Following Massive Ablation of Recurrent Sarcoma. Clin Surg. 2019; 4: 2639..